Swapnil Purushottam Borse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Swapnil Purushottam Borse has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Manish Nivsarkar
Department of Pharmacology, B.V. Patel Pharmaceutical Education and Research Development Centre, Ahmedabad, India
5 shared publications - Devendra Pratap Singh
Department of Pharmacology and Toxicology, B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, S. G. Highway, Thaltej, Ahmedabad 380054, Gujarat, India
4 shared publications Devendra Pratap Singh
Department of Pharmacology and Toxicology, B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad, Gujarat, 388054, India; NIRMA University, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat 382481, India
2 shared publicationsNeha Sharma
Translational Health Science and Technology Institute (THSTI), Faridabad, India
2 shared publicationsRita Rana
Department of Pharmacology and Toxicology, B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad, 380054, Gujarat, India
2 shared publications- Yashwant Kumar
Non-communicable Disease Centre, Translational Health Science and Technology Institute (THSTI), NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, Haryana, India
2 shared publications
Latest Publications
- Open Access
- 12 October 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 973768
In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb−drug interactions in the management of COVID-19
Ayurvedic medicines Withania somnifera Dunal (ashwagandha) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. The present study explores the effect of Ashwagandha and AYUSH-64 on important human CYP enzymes (CYP3A4, CYP2C8, and CYP2D6) to assess their interaction with remdesivir, a drug used for COVID-19 management during the second wave. The study also implies possible herb−drug interactions as ashwagandha and AYUSH-64 are being used for managing various pathological conditions. Aqueous extracts of ashwagandha and AYUSH-64 were characterized using LC-MS/MS. A total of 11 and 24 phytoconstituents were identified putatively from ashwagandha and AYUSH-64 extracts, respectively. In addition, in silico studies revealed good ADME properties of most of the phytoconstituents of these herbal drugs and suggested that some of these might possess CYP-450 inhibitory activity. In vitro CYP-450 studies with human liver microsomes showed moderate inhibition of CYP3A4, 2C8, and 2D6 by remdesivir, while ashwagandha had no inhibitory effect alone or in combination with remdesivir. AYUSH-64 also exhibited a similar trend; however, a moderate inhibitory effect on CYP2C8 was noticed. Thus, ashwagandha seems to be safe to co-administer with the substrates of CYP3A4, CYP2C8, and CYP2D6. However, caution is warranted in prescribing AYUSH-64 along with CYP2C8 substrate drugs. Furthermore, preclinical and clinical PK studies would be helpful for their effective and safer use in the management of various ailments along with other drugs.
- 12 October 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 973768
Open AccessIn vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb−drug interactions in the management of COVID-19
Ayurvedic medicines Withania somnifera Dunal (ashwagandha) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. The present study explores the effect of Ashwagandha and AYUSH-64 on important human CYP enzymes (CYP3A4, CYP2C8, and CYP2D6) to assess their interaction with remdesivir, a drug used for COVID-19 management during the second wave. The study also implies possible herb−drug interactions as ashwagandha and AYUSH-64 are being used for managing various pathological conditions. Aqueous extracts of ashwagandha and AYUSH-64 were characterized using LC-MS/MS. A total of 11 and 24 phytoconstituents were identified putatively from ashwagandha and AYUSH-64 extracts, respectively. In addition, in silico studies revealed good ADME properties of most of the phytoconstituents of these herbal drugs and suggested that some of these might possess CYP-450 inhibitory activity. In vitro CYP-450 studies with human liver microsomes showed moderate inhibition of CYP3A4, 2C8, and 2D6 by remdesivir, while ashwagandha had no inhibitory effect alone or in combination with remdesivir. AYUSH-64 also exhibited a similar trend; however, a moderate inhibitory effect on CYP2C8 was noticed. Thus, ashwagandha seems to be safe to co-administer with the substrates of CYP3A4, CYP2C8, and CYP2D6. However, caution is warranted in prescribing AYUSH-64 along with CYP2C8 substrate drugs. Furthermore, preclinical and clinical PK studies would be helpful for their effective and safer use in the management of various ailments along with other drugs.
- Open Access
- 27 June 2022
- Published by Springer Nature in Research Square
Effect of Diabetes mellitus on pharmacokinetics of metformin and telmisartan by using novel HPLC-UV method: A drug-disease interaction study
Metformin and Telmisartan are commonly co-prescribed drugs in diabetes plus hypertensive patients. Diabetes caused pharmacokinetic alterations in metformin due to alterations in drug metabolizing enzymes (DMEs) and/or transporters. But, there are no such reports for telmisartan alone or with metformin. Considering this, a simple, precise, robust, specific, and sensitive RP-HPLC method for simultaneous quantification of metformin and telmisartan in rat plasma were developed. Chromatographic separation achieved on cyano column with mobile phase consisting acetonitrile:10mM KH2PO4, pH 4.5 (60:40). Flow rate was 1.0mL/min. Detection wavelength was 237nm. The protein precipitation of both drugs from rat plasma was done using acetonitrile (recoveries ≥ 80%). HPLC bioanalytical calibration curve was found linear in the range of 10-3200ng/mL. Parameters like precision, accuracy, and stability were within accepted criteria for biomedical analysis. The developed method was successfully used for pharmacokinetic studies in normal and diabetic rats. Metformin (50mg/kg, p.o.; b.i.d.) and telmisartan (4mg/kg, p.o.; o.d.) were administered simultaneously. Diabetes significantly increased systemic exposure (increased AUC0 − t, Cmax; decreased CL, Vd) of metformin and telmisartan. This may be because of diabetes mediated increased SERT expression, decreased CYP2C11 and UGTs expression. Important to note that telmisartan doesn’t cause metformin PK alterations and vice-versa, in diabetic and normal rats.
- 27 June 2022
- Published by Springer Nature in Research Square
Open AccessEffect of Diabetes mellitus on pharmacokinetics of metformin and telmisartan by using novel HPLC-UV method: A drug-disease interaction study
Metformin and Telmisartan are commonly co-prescribed drugs in diabetes plus hypertensive patients. Diabetes caused pharmacokinetic alterations in metformin due to alterations in drug metabolizing enzymes (DMEs) and/or transporters. But, there are no such reports for telmisartan alone or with metformin. Considering this, a simple, precise, robust, specific, and sensitive RP-HPLC method for simultaneous quantification of metformin and telmisartan in rat plasma were developed. Chromatographic separation achieved on cyano column with mobile phase consisting acetonitrile:10mM KH2PO4, pH 4.5 (60:40). Flow rate was 1.0mL/min. Detection wavelength was 237nm. The protein precipitation of both drugs from rat plasma was done using acetonitrile (recoveries ≥ 80%). HPLC bioanalytical calibration curve was found linear in the range of 10-3200ng/mL. Parameters like precision, accuracy, and stability were within accepted criteria for biomedical analysis. The developed method was successfully used for pharmacokinetic studies in normal and diabetic rats. Metformin (50mg/kg, p.o.; b.i.d.) and telmisartan (4mg/kg, p.o.; o.d.) were administered simultaneously. Diabetes significantly increased systemic exposure (increased AUC0 − t, Cmax; decreased CL, Vd) of metformin and telmisartan. This may be because of diabetes mediated increased SERT expression, decreased CYP2C11 and UGTs expression. Important to note that telmisartan doesn’t cause metformin PK alterations and vice-versa, in diabetic and normal rats.
- Open Access
- 29 December 2021
- Published by Springer Nature in Research Square
CYP-450 Mediated Herb-Drug Interactions of Ashwagandha and AYUSH-64 Used in COVID-19 Integrative Management: A Case Example of Remdesivir
AimWithania somnifera Dunal (WS), known as Ashwagandha and AYUSH-64, a polyherbal formulation are repurposed for the management of COVID-19. The extensive use of these botanicals as home remedy along with other drugs for managing multifarious disease conditions is increasing over nations. This raises high chances of herb-drug interactions (HDIs) which may be beneficial, harmful, or even fatal. Therefore, current study aimed to explore the CYP mediated herb-drug interactions (HDIs) of Ashwagandha and AYUSH-64 along with case example of remdesivir to harness the best of these HDIs for integrative management of COVID-19Materials and MethodsThe aqueous extract of Ashwagandha and AYUSH-64 were characterized by LC-MS/MS. The in-silico pharmacokinetic (ADME) parameters were studied by using ADME tool. The in-vitro CYP-450 (CYP3A4, 2C8, 2D6) inhibition studies of WS and AYUSH-64 alone and in combination with a remdesivir were carried out resembling clinically scenario.ResultsTotal of 11 and 24 phytoconstituents were identified from the aqueous extract of Aswagandha and AYUSH-64. The in-silico ADME studies revealed that most of the phytoconstituents showed good oral bioavailability, drug likeliness, GI affinity and some of them displayed CYP-450 inhibitory activity. The in-vitro CYP-450 studies of remdesivir showed moderate inhibitory effect on CYP3A4, 2C8, 2D6. The aqueous extract of Aswagandha did not show any inhibitory activity towards all the studied CYP’s alone and in combination with remdesivir (IC50 >100µg/ml). Whereas, AYUSH-64 also followed the same trend but showed moderate inhibitory effect on CYP2C8 (IC50 ConclusionAswagandha did not exhibit HDIs with the CYP3A4, CYP2C8 and CYP2D6 thereby seem to be safe to co-administer with respective substrates. Whereas, AYUSH-64 only showed moderate HDIs towards CYP2C8 substrate among studied CYP enzymes. Caution is therefore warranted for prescribing AYUSH 64 along with CYP2C8 substrate drugs.
- 29 December 2021
- Published by Springer Nature in Research Square
Open AccessCYP-450 Mediated Herb-Drug Interactions of Ashwagandha and AYUSH-64 Used in COVID-19 Integrative Management: A Case Example of Remdesivir
AimWithania somnifera Dunal (WS), known as Ashwagandha and AYUSH-64, a polyherbal formulation are repurposed for the management of COVID-19. The extensive use of these botanicals as home remedy along with other drugs for managing multifarious disease conditions is increasing over nations. This raises high chances of herb-drug interactions (HDIs) which may be beneficial, harmful, or even fatal. Therefore, current study aimed to explore the CYP mediated herb-drug interactions (HDIs) of Ashwagandha and AYUSH-64 along with case example of remdesivir to harness the best of these HDIs for integrative management of COVID-19Materials and MethodsThe aqueous extract of Ashwagandha and AYUSH-64 were characterized by LC-MS/MS. The in-silico pharmacokinetic (ADME) parameters were studied by using ADME tool. The in-vitro CYP-450 (CYP3A4, 2C8, 2D6) inhibition studies of WS and AYUSH-64 alone and in combination with a remdesivir were carried out resembling clinically scenario.ResultsTotal of 11 and 24 phytoconstituents were identified from the aqueous extract of Aswagandha and AYUSH-64. The in-silico ADME studies revealed that most of the phytoconstituents showed good oral bioavailability, drug likeliness, GI affinity and some of them displayed CYP-450 inhibitory activity. The in-vitro CYP-450 studies of remdesivir showed moderate inhibitory effect on CYP3A4, 2C8, 2D6. The aqueous extract of Aswagandha did not show any inhibitory activity towards all the studied CYP’s alone and in combination with remdesivir (IC50 >100µg/ml). Whereas, AYUSH-64 also followed the same trend but showed moderate inhibitory effect on CYP2C8 (IC50 ConclusionAswagandha did not exhibit HDIs with the CYP3A4, CYP2C8 and CYP2D6 thereby seem to be safe to co-administer with respective substrates. Whereas, AYUSH-64 only showed moderate HDIs towards CYP2C8 substrate among studied CYP enzymes. Caution is therefore warranted for prescribing AYUSH 64 along with CYP2C8 substrate drugs.
- Open Access
Randomized, double blind, placebo controlled, clinical trial to study co-administration of Ashwagandha on safety, immunogenicity, and protection with COVID-19 vaccine – A Study Protocol
Introduction The government of India has rolled out COVID-19 vaccine program for individuals who are 18 years of age and above and priority is being given to the elderly, and individuals with morbidity. Oxford-AstraZeneca COVID-19 vaccine (COVISHIELD™) is most widely used in India. A large number of Indian people have been consuming various traditional medicines in the hope of better protection against COVID-19 infection. Several studies have reported immunological benefits of Ashwagandha and its potential as vaccine adjuvant. We plan to study co-administration of Ashwagandha with COVISHIELD™ vaccine on safety, immunogenicity and protection. Methods and analysis We designed a prospective, randomized, double blind, parallel group, placebo controlled, two arm, exploratory study on healthy volunteers receiving the COVISHIELD™ vaccine. In addition to the two dose schedule of COVISHIELD vaccine as per national guidelines, participants will be administered 8gm Ashwagandha or placebo tablets respectively per day. Primary outcome measure is immunogenicity as measured by SARS-CoV-2 spike (S1) and RBD-specific IgG antibody titres. Secondary outcome measures are safety, protective immune response and quality of life measures. Adverse event following immunization will be monitored at each time throughout the study. Participants will be tracked on a daily basis with a user friendly mobile phone application. Following power calculation 600 participants will be recruited per arm to demonstrate superiority by a margin of 7% with 80% power. Study duration is 28 weeks with interim analysis at the end of 12 weeks. Ethics and dissemination Ethical approval was obtained through the Central and institutional Ethics Committees. Participant recruitment is expected to commence by August 2021. Results will be presented in conferences and published in preprint followed by peer-reviewed medical journals. Registration details Clinical Trial Registry – India (CTRI) Registration Number: CTRI/2021/06/034496. Date of Registration June 30, 2021. Strengths and limitations of this study Novel study to demonstrate effect of coadministration of immune adjuvant and COVID-19 vaccine on safety and immunogenicity. Randomised placebo controlled 28 weeks study with 80 percent power to demonstrate role of putative natural immunomodulator to augment the protection and reduce breakthrough infections State of art immune assays to measure specific antibodies to SARS-CoV-2 to demonstrate both persistent and late upsurge in immune response Daily tracking of participants using a study specific designed mobile app An interim analysis is planned to provide information on early immune response after first dose of vaccine Participants may be reluctant to donate blood repeatedly for immune assays; compliance with the test drug may be a challenge; asymptomatic infections may be missed; the study is not measuring cellular immune response.
Open AccessRandomized, double blind, placebo controlled, clinical trial to study co-administration of Ashwagandha on safety, immunogenicity, and protection with COVID-19 vaccine – A Study Protocol
Introduction The government of India has rolled out COVID-19 vaccine program for individuals who are 18 years of age and above and priority is being given to the elderly, and individuals with morbidity. Oxford-AstraZeneca COVID-19 vaccine (COVISHIELD™) is most widely used in India. A large number of Indian people have been consuming various traditional medicines in the hope of better protection against COVID-19 infection. Several studies have reported immunological benefits of Ashwagandha and its potential as vaccine adjuvant. We plan to study co-administration of Ashwagandha with COVISHIELD™ vaccine on safety, immunogenicity and protection. Methods and analysis We designed a prospective, randomized, double blind, parallel group, placebo controlled, two arm, exploratory study on healthy volunteers receiving the COVISHIELD™ vaccine. In addition to the two dose schedule of COVISHIELD vaccine as per national guidelines, participants will be administered 8gm Ashwagandha or placebo tablets respectively per day. Primary outcome measure is immunogenicity as measured by SARS-CoV-2 spike (S1) and RBD-specific IgG antibody titres. Secondary outcome measures are safety, protective immune response and quality of life measures. Adverse event following immunization will be monitored at each time throughout the study. Participants will be tracked on a daily basis with a user friendly mobile phone application. Following power calculation 600 participants will be recruited per arm to demonstrate superiority by a margin of 7% with 80% power. Study duration is 28 weeks with interim analysis at the end of 12 weeks. Ethics and dissemination Ethical approval was obtained through the Central and institutional Ethics Committees. Participant recruitment is expected to commence by August 2021. Results will be presented in conferences and published in preprint followed by peer-reviewed medical journals. Registration details Clinical Trial Registry – India (CTRI) Registration Number: CTRI/2021/06/034496. Date of Registration June 30, 2021. Strengths and limitations of this study Novel study to demonstrate effect of coadministration of immune adjuvant and COVID-19 vaccine on safety and immunogenicity. Randomised placebo controlled 28 weeks study with 80 percent power to demonstrate role of putative natural immunomodulator to augment the protection and reduce breakthrough infections State of art immune assays to measure specific antibodies to SARS-CoV-2 to demonstrate both persistent and late upsurge in immune response Daily tracking of participants using a study specific designed mobile app An interim analysis is planned to provide information on early immune response after first dose of vaccine Participants may be reluctant to donate blood repeatedly for immune assays; compliance with the test drug may be a challenge; asymptomatic infections may be missed; the study is not measuring cellular immune response.
- 1 October 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 106, 1513-1526
In vitro and in vivo anticancer efficacy potential of Quercetin loaded polymeric nanoparticles
- 1 October 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 106, 1513-1526
In vitro and in vivo anticancer efficacy potential of Quercetin loaded polymeric nanoparticles
- 1 September 2016
- Published by Elsevier in Translational Research
- Vol. 175, 76-91
Clinical importance of nonsteroidal anti-inflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target
- 1 September 2016
- Published by Elsevier in Translational Research
- Vol. 175, 76-91
Clinical importance of nonsteroidal anti-inflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target
- 1 March 2016
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 78, 66-75
A novel model for NSAID induced gastroenteropathy in rats
- 1 March 2016
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 78, 66-75
A novel model for NSAID induced gastroenteropathy in rats